Wednesday, July 20, 2022

Bottom is in

Bottom is in

Corona Del Mar, CA

 

Hey ,

 

I'm naturally a contrarian.

 

I know from experience, the prevailing theme on Wall Street tends to be wrong.

 

I don't think you should stack indicators together without testing them together (too many cooks in the kitchen), but here's a list of technical observations that are all bullish for the stock market:

 

  1. The COT shows small speculators selling short the S&P 500 en mass
  2. AAII sentiment has been very low (along with price behavior)
  3. 90% up volume day on NYSE yesterday
  4. Our True Asset Price strategy has the S&P 500 on a buy signal for the past week
  5. Yesterday saw IWM gain > QQQ > SPY > DIA. That was a good setup for a momentum trade back when I was trading intraday
  6. Looks like a Dow Theory buy signal

The negative things I can think about off the top of my head are all fundamental analysis...which I'm no good at and I've learned to NEVER factor into my trading.

 

Fundamental analysis tends to be backward looking and useless for trading.

 

My economics teacher had a doctorate, and drove a beat up old Honda to work.

 

He said the markets couldn't be beat. Efficient Market Hypothesis and all that jazz.

 

This is what happens when you live in a bubble and choose not to look at empirical evidence.

 

Trade smart,

 

Dan "Prince of Proof" Murphy

 

 

 

 

 

 

 

 

 

 

 

 

 

Portfolio Boss, Inc.

260 Newport Center Dr, Suite 100 Newport Beach, CA 92660

 

Don't want to stay in the loop with Dan? We'll be sad to see you go, but you can unsub to no longer receive emails.

 

Government required disclaimer: The results listed herein are based on hypothetical trades. Plainly speaking, these trades were not actually executed. Hypothetical or simulated performance results have certain inherent limitations. Unlike an actual performance record, simulated results do not represent actual trading. Also, since the trades have not actually been executed, the results may have under (or over) compensated for the impact, if any, of certain market factors such as lack of liquidity. You may have done better or worse than the results portrayed.

No comments:

Post a Comment

Nivolumab Appears to Boost Cure Rate in Advanced Hodgkin Lymphoma - Cancer Currents Blog

The latest from the NCI Cancer Currents blog Having trouble viewing this email? View it as a Web...